行情

INSM

INSM

Insmed
NASDAQ

实时行情|Nasdaq Last Sale

18.35
+0.64
+3.61%
盘后: 18.35 0 0.00% 16:00 04/08 EDT
开盘
18.10
昨收
17.71
最高
18.84
最低
17.54
成交量
143.00万
成交额
--
52周最高
34.94
52周最低
12.09
市值
16.49亿
市盈率(TTM)
-6.0336
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测INSM价格均价为46.78,最高价位56.00,最低价为36.00。

EPS

INSM 新闻

更多
  • Hedge Funds Are Crazy About Insmed Incorporated (INSM)
  • Insider Monkey · 1天前
  • Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire · 5天前
  • Insmed Appoints Carol A. Schafer to its Board of Directors
  • PR Newswire · 6天前
  • The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
  • Benzinga · 03/18 11:36

所属板块

生物技术和医学研究
+3.08%
制药与医学研究
+2.83%

热门股票

代码
价格
涨跌幅

INSM 简况

Insmed Incorporated is a global biopharmaceutical company. The Company’s product ARIKAYCE (amikacin liposome inhalation suspension) is developed for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that offers a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.
展开

微牛提供Insmed Incorporated(NASDAQ-INSM)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的INSM股票新闻,以帮助您做出投资决策。